Home/Pipeline/TG-1801

TG-1801

B-Cell Malignancies

Phase 1Active

Key Facts

Indication

B-Cell Malignancies

Phase

Phase 1

Status

Active

Company

TG Therapeutics

About TG Therapeutics

TG Therapeutics has successfully transitioned into a commercial entity with the FDA approval of BRIUMVI for relapsing multiple sclerosis, establishing a core revenue stream. The company's strategy is anchored on its proprietary glycoengineering platform, which enhances antibody potency to target CD20 on B-cells. This validated approach underpins its pipeline expansion into broader autoimmune and oncology indications, aiming to capture significant market share in competitive therapeutic landscapes.

View full company profile

Therapeutic Areas

Multiple Sclerosis Hematologic Malignancies Autoimmune Diseases

Other B-Cell Malignancies Drugs

Drug	Company	Phase	Status
CAR-T Program (Hematological)	XellSmart	Phase 1	Active
BAFFR Allo CAR-NK Cells	PeproMene Bio	Pre-clinical	Active
IKS03	Iksuda Therapeutics	Clinical	Active
TNB-486	Ancora Bio	Phase 1	Active
docirbrutinib (AS-1763)	Carna Biosciences	Phase 1b	Active
Abivertinib	Sorrento Therapeutics	Phase 1/2	Active
Kymriah® (tisagenlecleucel)	Novartis	Approved	Active
KITE-363	Gilead Sciences	Phase 1/2	Active
HSK29116	Haisco Pharmaceutical Group	Phase I/II	Active
TG-1701	TG Therapeutics	Phase 1	Active
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
Plamotamab (XmAb®13676)	Xencor	Phase 2	Active (Partnered)